Nearly 100 medicines for sale in the U.S. have now received pediatric labeling reversing a period when not enough studies were being done in this population. This welcome development follows recent legislation to provide incentives for drug makers who focus on the pediatric segment.
The Case for Pediatric Formulations: The rights of children are coming to the forefront and altering the way clinicians, politicians and policy-makers view this vulnerable segment of population.
By Dr. Jon Bruss, MD, MSPH, FAAP |